A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will compare two treatments for HIV-1 infection with the goal of therapy being to decrease the viral load to undetectable levels. In addition, the safety and efficacy of GW433908/ritonavir versus lopinavir/ritonavir (Kaletra) will be assessed. Approximately 866 subjects will be enrolled in this multi-center study with an expected participation of 10 subjects at this site. Study participation will last approximately 52 weeks and will require 12 study visits. Study procedures include medical histories, physical exams, HIV-associated condition assessments, blood tests, pharmacokinetic analysis, and optional pharmacogenetic testing